307302-08-5

Basic information

• Product Name: 3-[(4-methylbenzyl)oxy]benzoic acid
• Synonyms: 3-[(4-methylbenzyl)oxy]benzoic acid
• CAS NO: 307302-08-5
• Molecular Formula: C₁₅H₁₄O₃
• Molecular Weight: 242.26986
• Mol File: 307302-08-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(4-methylbenzyl)oxy]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(4-methylbenzyl)oxy]benzoic acid(307302-08-5)
• EPA Substance Registry System: 3-[(4-methylbenzyl)oxy]benzoic acid(307302-08-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 307302-08-5(Hazardous Substances Data)

Upstream product

• 7781-98-8 ethyl-3-hydroxybenzoate 
• 104-82-5 4-Methylbenzyl chloride 
• 74-88-4 methyl iodide 
• 99-06-9 3-Carboxyphenol 
• 19438-10-9 methyl 3-hydroxybenzoate 

Downstream Products

• 307302-10-9 3-(4-methylbenzoyloxy)-4'-(piperidinomethyl)benzanilide 
• 1160250-74-7 C₁₅H₁₃ClO₂ 

Relevant articles and documents

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors

Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.

Cyclic compounds and uses thereof

Compounds of general formula (1) R1—X1—W—X2—Z1—Z2—R2 or salts thereof, exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1is an optionally substituted five- or six-membered ring group; X1is a free valency or the like; W is a divalent group represented by, e. g., general formula (2) (wherein A and B are each an optionally substituted five- to seven-membered ring; E1and E4are each optionally substituted carbon or the like; E2and E3are each oxygen or the like; and a and b are each a single bond or a double bond); X2is a divalent group constituting a straight chain moiety; Z1is a divalent cyclic group or the like; Z2is a free valency or the like; and R2is optionally substituted amino or the like.

CYCLIC COMPOUNDS AND USES THEREOF

Compounds of general formula (1) or salts thereof, exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group represented by, e. g., general formula (2) (wherein A and B are each an optionally substituted five-to seven-membered ring; E1 and E4 are each optionally substituted carbon or the like; E2 and E3 are each oxygen or the like; and a and b are each a single bond or a double bond); X2 is a divalent group constituting a straight chain moiety; Z1 is a divalent cyclic group or the like; Z2 is a free valency or the like; and R2 is optionally substituted amino or the like.